Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-08-14 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023Summarized terms for warrants series TO2: Each unit in the Rights Issue consisted of five (5) shares and three (3) warrants series TO2. Each warrant series TO2 entitles to subscription of one (1) new share in the Company. The exercise price for warrants series TO2 has been determined as 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the measurement period, which ran from and including July 28, 2023, up to and including August 10, 2023. During the measurement period, the volume-weighted average price in the Company’s share was approximately SEK 0.94, therefore, the exercise price for warrants series TO2 is SEK 0.66. The exercise period for warrants series TO2 runs during the period from and including August 14, 2023, up to and including August 25, 2023. If all warrants series TO2 are exercised, the Company will receive approximately SEK 5.7 million before issuing costs. In order for the warrants not to expire and lose their value, it is required that the holder actively subscribes for new shares no later than August 25, 2023, or sells the warrants no later than August 22, 2023. Please observe that certain nominees might close their application earlier than August 25, 2023. Please note that warrants that are not exercised no later than August 25, 2023, or sold no later than August 22, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. How warrants are exercised: Direct-registered warrants (Securities account) The application form including instructions for payment will be available at the Company’s website, www.Biosergen.net. Advisors |
||||
2023-08-11 | Biosergen | Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Biosergen | Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Biosergen | Biosergen AB: Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Biosergen | Biosergen AB: Biosergen publishes 2022 annual report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Biosergen | Notice of annual general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Reduced risk after positive phase 1-studies - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Minskad risk efter positiva fas 1-studier - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Carlsquare | Carlsquare: Mrkt BUZZ, Biosergen: Plans for speedy development of lead candidate | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Biosergen | Biosergen AB: Biosergen provides Phase 2 clinical development strategy update | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-28 | Biosergen | Biosergen AB: Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Biosergen will be participating at Mangold Insight Investor Day, March 22 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Carlsquare has initiated its coverage of Biosergen | Pressreleaser | Visa Stäng |
|
||||
2023-03-20 | Carlsquare | Carlsquare: Initiation of coverage, Biosergen: Make antifungals great again | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-13 | Biosergen | Biosergen AB: Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Fungicide with potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Svampdödare med potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-16 | Biosergen | Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-12-12 | Biosergen | Biosergen AB: The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-10-20 | Biosergen | Biosergen AB: Biosergen's warrants of series TO2 are admitted to trading | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-19 | Biosergen | Biosergen AB: Biosergen allocates shares to an underwriter in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-05 | Biosergen | Biosergen AB: Biosergen appoints Mangold Fondkommission to act as a liquidity provider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-04 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-26 | Biosergen | Biosergen AB: Mangold Insight publishes interview with Biosergen's CEO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-22 | Biosergen | Biosergen AB: Members of the board of directors and executive management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Biosergen | Biosergen AB: The subscription period in Biosergen's rights issue starts today | Pressreleaser | Visa Stäng |
|
||||
2022-09-08 | Biosergen | Biosergen AB: Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-02 | Biosergen | Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for second quarter 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen receives a loan of SEK 7 million to finance continued development | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Biosergen | Biosergen AB: Biosergen completes the third cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|